Vaccinex Enterprise Value Over E B I T D A from 2010 to 2024

VCNX Stock  USD 3.62  0.02  0.56%   
Vaccinex Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA will likely drop to -0.16 in 2024. During the period from 2010 to 2024, Vaccinex Enterprise Value Over EBITDA regression line of annual values had slope of  0.51 and arithmetic mean of (3.37). View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(0.15)
Current Value
(0.16)
Quarterly Volatility
2.50725602
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaccinex financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccinex's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 19.7 K or Depreciation And Amortization of 181 K, as well as many indicators such as Price To Sales Ratio of 7.19, Dividend Yield of 0.0 or Days Sales Outstanding of 451. Vaccinex financial statements analysis is a perfect complement when working with Vaccinex Valuation or Volatility modules.
  
Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

Latest Vaccinex's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Vaccinex over the last few years. It is Vaccinex's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaccinex's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Vaccinex Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(3.37)
Coefficient Of Variation(74.50)
Mean Deviation2.33
Median(3.69)
Standard Deviation2.51
Sample Variance6.29
Range5.6584
R-Value0.91
Mean Square Error1.16
R-Squared0.83
Slope0.51
Total Sum of Squares88.01

Vaccinex Enterprise Value Over E B I T D A History

2024 -0.16
2023 -0.15
2022 -1.09
2021 -1.01
2020 -1.34
2019 -1.89
2018 -0.46

About Vaccinex Financial Statements

Vaccinex investors use historical fundamental indicators, such as Vaccinex's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaccinex. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(0.15)(0.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.